Spark Therapeutics, Inc. (NASDAQ:ONCE)‘s stock had its “buy” rating reiterated by Cantor Fitzgerald in a research note issued to investors on Tuesday, Marketbeat Ratings reports. They currently have a $105.00 target price on the biotechnology company’s stock, up from their prior target price of $94.00. Cantor Fitzgerald’s target price indicates a potential upside of 21.81% from the company’s current price.
Other equities research analysts have also issued research reports about the company. Chardan Capital upgraded Spark Therapeutics from a “neutral” rating to a “buy” rating and upped their target price for the company from $60.00 to $100.00 in a research report on Wednesday, August 2nd. Jefferies Group LLC reiterated a “buy” rating and issued a $85.00 target price on shares of Spark Therapeutics in a research report on Monday, July 24th. UBS AG reiterated a “buy” rating and issued a $92.00 target price (up previously from $70.00) on shares of Spark Therapeutics in a research report on Thursday, August 3rd. Stifel Nicolaus reiterated a “buy” rating and issued a $92.00 target price (up previously from $77.00) on shares of Spark Therapeutics in a research report on Thursday, August 3rd. Finally, BidaskClub upgraded Spark Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, August 26th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and eighteen have given a buy rating to the stock. Spark Therapeutics has an average rating of “Buy” and a consensus price target of $89.92.
Shares of Spark Therapeutics (ONCE) opened at 86.20 on Tuesday. The stock’s market cap is $2.69 billion. Spark Therapeutics has a one year low of $35.07 and a one year high of $91.00. The stock’s 50 day moving average is $85.92 and its 200-day moving average is $85.92.
Spark Therapeutics (NASDAQ:ONCE) last issued its earnings results on Wednesday, August 2nd. The biotechnology company reported ($1.89) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.75) by ($0.14). The firm had revenue of $1.48 million during the quarter, compared to analysts’ expectations of $1.33 million. Spark Therapeutics had a negative net margin of 962.72% and a negative return on equity of 59.74%. Spark Therapeutics’s quarterly revenue was up 14.7% on a year-over-year basis. During the same quarter in the prior year, the company earned ($1.04) EPS. On average, equities analysts forecast that Spark Therapeutics will post ($7.67) EPS for the current year.
ILLEGAL ACTIVITY NOTICE: “Spark Therapeutics, Inc. (ONCE) Rating Reiterated by Cantor Fitzgerald” was originally reported by Stock Observer and is owned by of Stock Observer. If you are accessing this article on another site, it was stolen and republished in violation of US and international trademark & copyright laws. The original version of this article can be read at https://www.thestockobserver.com/2017/10/10/spark-therapeutics-once-buy-rating-reaffirmed-at-cantor-fitzgerald.html.
In other news, insider Daniel Faga sold 3,000 shares of the company’s stock in a transaction that occurred on Monday, July 24th. The stock was sold at an average price of $70.00, for a total transaction of $210,000.00. Following the completion of the transaction, the insider now directly owns 3,000 shares of the company’s stock, valued at approximately $210,000. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Hospital Of Philade Children’s sold 1,000,000 shares of the company’s stock in a transaction that occurred on Thursday, September 21st. The stock was sold at an average price of $84.63, for a total value of $84,630,000.00. Following the transaction, the director now directly owns 3,928,707 shares of the company’s stock, valued at $332,486,473.41. The disclosure for this sale can be found here. In the last 90 days, insiders sold 1,333,195 shares of company stock worth $109,070,506. Insiders own 7.30% of the company’s stock.
Hedge funds have recently made changes to their positions in the company. Ameritas Investment Partners Inc. raised its stake in shares of Spark Therapeutics by 23.6% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,040 shares of the biotechnology company’s stock worth $122,000 after buying an additional 389 shares during the period. Cubist Systematic Strategies LLC acquired a new position in shares of Spark Therapeutics during the 2nd quarter worth approximately $143,000. BNP Paribas Arbitrage SA raised its stake in shares of Spark Therapeutics by 530.1% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 2,911 shares of the biotechnology company’s stock worth $174,000 after buying an additional 2,449 shares during the period. Pacad Investment Ltd. raised its stake in shares of Spark Therapeutics by 75.0% during the 2nd quarter. Pacad Investment Ltd. now owns 3,500 shares of the biotechnology company’s stock worth $209,000 after buying an additional 1,500 shares during the period. Finally, Highbridge Capital Management LLC acquired a new position in shares of Spark Therapeutics during the 1st quarter worth approximately $227,000. 77.84% of the stock is owned by institutional investors and hedge funds.
Spark Therapeutics Company Profile
Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.
Receive News & Ratings for Spark Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.